Tag
A large randomized trial finds no difference in 90-day days alive and out of hospital between early vasopressors with restricted fluids versus higher fluids with delayed vasopressors in septic shock, though pulmonary edema was less frequent
A multicenter randomized trial found that initiating a 1-hour resuscitation bundle including early antibiotics, fluids, vasopressors, and hydrocortisone in the prehospital setting did not significantly reduce 28-day mortality in adults with
Persistent tissue hypoperfusion alongside vasopressor dosing improves early risk stratification in refractory septic shock, identifying patients with markedly increased 28-day mortality beyond vasopressor dose alone, as shown in a secondary
A randomized trial in 156 emergency acute-abdomen patients found phenylephrine and norepinephrine produced similar postoperative RAAS changes and complication rates; norepinephrine produced an early renin rise, while high preoperative renin
A systematic review of 17 randomized trials (n=4,259) found no consistent renoprotective effect from any vasopressor in septic shock. Heterogeneous definitions, underpowered studies, and reliance on RRT limit conclusions; standardized renal
In a double-blind RCT of 130 patients with refractory septic shock, terlipressin increased the proportion achieving MAP ≥65 mmHg with low catecholamine exposure at 6 hours versus placebo but did not change 28-day mortality; digital ischemia
A single‑center RCT found that starting a titrated norepinephrine infusion at anesthesia induction reduced intraoperative hypotension and lowered 30‑day medico‑surgical complications compared with reactive ephedrine boluses in high‑risk abd
This study evaluates factors influencing vasopressor route choice in sepsis and demonstrates low complication rates associated with peripheral administration, supporting its safety in early resuscitation.
An international study reveals that postoperative vasopressor infusions after noncardiac surgery vary widely across hospitals and are linked to higher mortality and complications, highlighting the need for optimized management strategies.
This trial evaluated low-dose hydrocortisone in cirrhotic patients with septic shock, finding no improvement in 28-day mortality or shock resolution compared to placebo.
